Concurrent atypical myopathy and equine dysautonomia in two horses.

This research article discusses the coincidental occurrence of two rare equine diseases — atypical myopathy (AM) and equine grass sickness (EGS) — in two horses, looking into their clinical and pathological manifestations, and exploring possible common predisposing factors.

Overview of the Research

• The research focuses on two horses which simultaneously presented symptoms of Atypical Myopathy (AM) and Equine Grass Sickness (EGS), two rare diseases that affect horses. The study delves into the clinical details and pathological lesions associated with these conditions.
• The occurrence of both conditions in the same animals is not considered a mere coincidence given the rarity of these diseases. However, the study does not imply that both conditions share a common cause, but rather suggests that certain factors may predispose horses to both diseases.

Detailed Explanation of the Diseases

• Atypical Myopathy (AM) is an often fatal disease affecting the muscles of horses. Symptoms can be sudden and include stiffness, difficulty moving, muscle pain and dark colored urine due to muscle damage.
• Equine Grass Sickness (EGS), also known as dysautonomia, is a disease that affects a horse’s nervous system, more specifically the part of the nervous system responsible for controlling involuntary functions. Symptoms can include difficulties swallowing, weight loss and colic.
• While these diseases are distinct, the concurrent presentation of both conditions in the two horses implies possible interplay or common elements that increase the likelihood of their occurrence.

Identifying Common Predisposing Causes

• This research aims to explore if there are common factors or conditions that could increase the susceptibility of horses to both AM and EGS. These could include environmental factors, genetic predisposition, or exposure to certain toxins or diseases.
• The detection of such predisposing factors could be significant in the prevention, detection, and treatment strategies for both AM and EGS, potentially reducing their incidences and improving survival rates for affected horses.